Caseware UK (AP4) 2024.0.164 2024.0.164 2024-09-302024-09-302025-05-22medical equipmenttrue2023-10-01truefalse11The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 10389019 2023-10-01 2024-09-30 10389019 2022-10-01 2023-09-30 10389019 2024-09-30 10389019 2023-09-30 10389019 c:Director1 2023-10-01 2024-09-30 10389019 d:CurrentFinancialInstruments 2024-09-30 10389019 d:CurrentFinancialInstruments 2023-09-30 10389019 d:CurrentFinancialInstruments d:WithinOneYear 2024-09-30 10389019 d:CurrentFinancialInstruments d:WithinOneYear 2023-09-30 10389019 d:ShareCapital 2024-09-30 10389019 d:ShareCapital 2023-09-30 10389019 d:RetainedEarningsAccumulatedLosses 2024-09-30 10389019 d:RetainedEarningsAccumulatedLosses 2023-09-30 10389019 c:FRS102 2023-10-01 2024-09-30 10389019 c:AuditExempt-NoAccountantsReport 2023-10-01 2024-09-30 10389019 c:FullAccounts 2023-10-01 2024-09-30 10389019 c:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 10389019 e:PoundSterling 2023-10-01 2024-09-30 iso4217:GBP xbrli:pure

Registered number: 10389019









MEARNS MEDICAL EQUIPMENT LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 SEPTEMBER 2024

 
MEARNS MEDICAL EQUIPMENT LIMITED
REGISTERED NUMBER: 10389019

BALANCE SHEET
AS AT 30 SEPTEMBER 2024

2024
2023
Note
£
£

  

Current assets
  

Cash at bank and in hand
 4 
146
1,280

  
146
1,280

Creditors: amounts falling due within one year
 5 
(11,094)
(10,634)

Net current liabilities
  
 
 
(10,948)
 
 
(9,354)

Total assets less current liabilities
  
(10,948)
(9,354)

  

Net liabilities
  
(10,948)
(9,354)


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
(11,048)
(9,454)

  
(10,948)
(9,354)


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




D Mearns
Director

Date: 22 May 2025

Page 1

 
MEARNS MEDICAL EQUIPMENT LIMITED
REGISTERED NUMBER: 10389019
    
BALANCE SHEET (CONTINUED)
AS AT 30 SEPTEMBER 2024

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
MEARNS MEDICAL EQUIPMENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

1.


General information

Mearns Medical Equipment Limited is a company limited by shares and incorporated in England & Wales under the Companies Act 2006. The address of the registered office is given on the Company information page. The nature of the Company's operations and its principal activities are set out in the Directors’ report. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Going concern

At the time of approving the financial statements, the director has a reasonable expectation that
the company has adequate resources to continue in operational existence for the foreseeable future. The director will continue his financial support. Therefore, the director has adopted the going concern basis of accounting in preparing the financial statements.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 3

 
MEARNS MEDICAL EQUIPMENT LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

2.Accounting policies (continued)

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2023 - 1).


4.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
146
1,280

146
1,280



5.


Creditors: Amounts falling due within one year

2024
2023
£
£

Other creditors
9,924
9,524

Accruals and deferred income
1,170
1,110

11,094
10,634



6.


Related party transactions

In other creditors there is a Directors loan of £9,934 (2023: £9,524) provided to the company. Interest of 0% is paid on this loan and it is repayable on demand.

 
Page 4